Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Cancer Gene Mutation”

2,611 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 2,611 results

Not applicableLooking for participantsNCT06643000
What this trial is testing

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Who this might be right for
Non-small Cell Lung CancerLeptomeningeal MetastasisEGFR Gene Mutation
Henan Cancer Hospital 60
Testing effectiveness (Phase 2)Ended earlyNCT01109615
What this trial is testing

Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations

Who this might be right for
Metastatic Colorectal Cancer
Vejle Hospital 40
Testing effectiveness (Phase 2)Study completedNCT01967576
What this trial is testing

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma

Who this might be right for
PheochromocytomaParaganglioma
National Cancer Institute (NCI) 14
Early research (Phase 1)Looking for participantsNCT06902376
What this trial is testing

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Who this might be right for
Anaplastic Thyroid CancerThyroid CancerBRAF Mutation-Related Tumors
UNC Lineberger Comprehensive Cancer Center 12
Testing effectiveness (Phase 2)Looking for participantsNCT06316960
What this trial is testing

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Who this might be right for
AML, ChildhoodRelapse/RecurrenceRefractory AML+2 more
Children's Hospital of Soochow University 50
Testing effectiveness (Phase 2)WithdrawnNCT02115035
What this trial is testing

A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib

Who this might be right for
Multiple Myeloma
University of Arkansas
Large-scale testing (Phase 3)UnknownNCT02633189
What this trial is testing

Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

Who this might be right for
Non-squamous Non-small Cell Lung Cancer
National Cancer Institute, Naples 200
Not applicableLooking for participantsNCT01689584
What this trial is testing

COsegregation of VARiants in Panel of Genes

Who this might be right for
Gene Mutation-Related CancerGenetic Predisposition
Institut Curie 3,500
Testing effectiveness (Phase 2)Ended earlyNCT02285855
What this trial is testing

Metformin in Non Small Cell Lung Cancer (NSCLC)

Who this might be right for
Lung Cancer
M.D. Anderson Cancer Center 27
Testing effectiveness (Phase 2)UnknownNCT02725918
What this trial is testing

Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure

Who this might be right for
Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 150
Not applicableUnknownNCT02666755
What this trial is testing

Novel Detection System for Lung Cancer Curative Effect Monitoring

Who this might be right for
Lung Neoplasms
Jian Zhang 160
Early research (Phase 1)Not Yet RecruitingNCT07372625
What this trial is testing

Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Who this might be right for
TP53 Y220C MutationAdvanced Solid Tumors
PMV Pharmaceuticals, Inc 14
Not applicableEnrolling By InvitationNCT06470685
What this trial is testing

Prophylactic Prostatectomy for Prostate Cancer (PPPC)

Who this might be right for
Prostate CancerGenetic Predisposition to DiseaseBRCA Mutation
Royal Marsden NHS Foundation Trust 20
Large-scale testing (Phase 3)Study completedNCT00608933
What this trial is testing

Education Intervention in Encouraging Health Providers to Talk With Cancer Patients About the Use of Complementary and Alternative Medicine

Who this might be right for
Unspecified Adult Solid Tumor, Protocol SpecificUnspecified Childhood Solid Tumor, Protocol Specific
M.D. Anderson Cancer Center 1,356
Early research (Phase 1)Study completedNCT03084640
What this trial is testing

Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma

Who this might be right for
Malignant Melanoma
Regeneron Pharmaceuticals 30
Testing effectiveness (Phase 2)Study completedNCT03736837
What this trial is testing

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07285148
What this trial is testing

Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerEGFR MutationMetastatic Lung Cancer+1 more
Beijing Pearl Biotechnology Limited Liability Company 253
Testing effectiveness (Phase 2)Active Not RecruitingNCT05445843
What this trial is testing

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Who this might be right for
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Novartis Pharmaceuticals 95
Testing effectiveness (Phase 2)UnknownNCT04689815
What this trial is testing

Oral Arsenic Trioxide for NPM1-mutated AML

Who this might be right for
NPMc+ AML
The University of Hong Kong 50
Not applicableStudy completedNCT04108117
What this trial is testing

Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction

Who this might be right for
Postoperative ComplicationsRecurrenceBreast Neoplasms+5 more
Severance Hospital 659
Load More Results